Bottom Line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
Bottom line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
For years, developing selective FGFE2/3 inhibitors has been hindered by the extreme structural similarity among FGFR family members, leading to toxicities and resistance with current therapies.
HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 ...
By analyzing murine and human pancreatic tissue specimens, Tonelli and colleagues found that compared with normal tissue, FGFR2 expression was higher in KRAS-mutated precancerous lesions and some KRAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results